Showing 6601-6610 of 7112 results for "".
- Celgene Announces Results From Ongoing Phase 3 LIBERATE Trial of Otezla for Psoriasishttps://practicaldermatology.com/news/celgene-announces-results-from-ongoing-phase-3-liberate-trial-of-otezla-for-psoriasis/2458838/Results from Celgene Corporation’s ongoing Phase 3 LIBERATE trial evaluating Otezla (apremilast) in patients with moderate to severe plaque psoriasis presented at 24th European Academy of Dermatology and Venereology show that half of psoriasis patients treated with oral Otezla achieved PASI
- SecurityMetrics: HIPAA Report Reveals Healthcare's Shortcomingshttps://practicaldermatology.com/news/hipaa-report-reveals-healthcares-shortcomings/2458840/A significant security disparity exists among healthcare c-suite and IT departments, outlined by the SecurityMetrics HIPAA Security Rule Report. In a survey of c-level, risk officers, and IT managers, a 10-20% gap was revealed between what executives believe is happening in regards to patient dat
- OHSU Releases Mole Mapper App to Track Potential Skin Cancershttps://practicaldermatology.com/news/ohsu-releases-mole-mapper-app-to-track-potential-skin-cancers/2458843/Oregon Health & Science University released an iPhone app it says is designed to advance melanoma research by giving users the ability to accurately measure and monitor moles, and contribute photos of how their potential trouble spots evolve over time. Called Mole Mapper, the app is free to d
- FDA Accepts sNDA for Dalvancehttps://practicaldermatology.com/news/fda-accepts-snda-for-dalvance/2458849/The FDA accepted Allergan's supplemental New Drug Application (sNDA) to expand the label to include single-dose administration of DALVANCE® (dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults caused by design
- Novan Appoints Chief Financial Officer and Chief Commercial Officer to Leadership Teamhttps://practicaldermatology.com/news/novan-appoints-chief-financial-officer-and-chief-commercial-officer-to-leadership-team/2458851/Novan Therapeutics appointed two new executives from the dermatology industry to the company's leadership team. Richard Peterson has joined the company as Chief Financial Officer and Brian Johnson as Chief Commercial Officer. Mr. Peterson will be responsible for the company's financi
- New Therapeutic Skin Care Line From Galdermahttps://practicaldermatology.com/news/new-therapeutic-skin-care-line-from-galderma/2458852/Galderma Laboratories, LP, makers of Cetaphil, unveiled a new therapeutic skincare line precisely engineered for challenged skin—Excipial. It will be available over the counter and without a prescription. Excipial products are formulated with ingredients to heal, relieve, protect, and repai
- Syneron Introduces PicoWay Resolvehttps://practicaldermatology.com/news/syneron-introduces-picoway-resolve/2458850/Syneron Medical Ltd. introduced the PicoWay Resolve™, a dual wavelength fractional modality for the PicoWay picosecond laser, at the 24th European Academy of Dermatology and Venereology (EADV) Congress in Copenhagen, Denmark, October 7-11, 2015. The launch of the new Resolve frac
- ZELTIQ Receives FDA Clearance to Treat Submental Fat With Coolsculpting Procedurehttps://practicaldermatology.com/news/zeltiq-receives-fda-clearance-to-treat-submental-fat-with-coolsculpting-procedure/2458855/The FDA granted an expanded clearance for ZELTIQ(R) Aesthetics, Inc.’s Coolsculpting procedure, paving the way for the introduction of the new, CoolMini(TM) applicator, which is designed to treat smaller pockets of fat, including the submental, or chin fat area. The CoolSculpting(R) procedu
- Revance Therapeutics Initiates Phase 3 Clinical Trial of Botulinum Toxin Type A Topical Gel for Crow's Feethttps://practicaldermatology.com/news/revance-therapeutics-initiates-phase-3-clinical-trial-of-botulinum-toxin-type-a-topical-gel-for-crows-feet/2458857/Revance Therapeutics, Inc. has commenced dosing patients in the Phase 3 pivotal study to evaluate the safety and efficacy of its RT001 investigational topical drug product candidate for the treatment of lateral canthal lines, or crow’s feet. The Phase 3 trial will evaluate the safety and ef
- 100,000 Join the ASPIRE Galderma Rewards Loyalty Program in First 90 dayshttps://practicaldermatology.com/news/100000-join-the-aspire-galderma-rewards-loyalty-program-in-the-first-90-days/2458867/Galderma’s ASPIRE Rewards program has enrolled 100,000 consumers since its launch on May 1, 2015. ASPIRE Galderma Rewards is a new loyalty program connecting US consumers and healthcare professionals using the Galderma family of aesthetic products. The vision of the Galderma a